A former OrbiMed Advisors co-portfolio manager is forming his own hedge fund firm.Via his New York-based Stratome Capital, Richard Klemm plans to take long and short positions in the shares of early-stage biotechnology companies. He is aiming to launch in September or October with at least $50 million from a single anchor investor.Klemm plans to hire at least two analysts to work with him. In May, he brought in Janine Krause as chief operating ...

full article to subscribers hfalert.